{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:35:53Z","timestamp":1760747753228,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ejca.2017.12.001","type":"journal-article","created":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T22:33:50Z","timestamp":1515105230000},"page":"122-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1"],"prefix":"10.1016","volume":"90","author":[{"given":"G.M.","family":"Haag","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Zoernig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Halama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Dick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Podola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Funk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ziegelmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Juenger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bucur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Umansky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.S.","family":"Falk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Karapanagiotou-Schenkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Beckhove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Enk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.12.001_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-0190","article-title":"Systematic review of medical treatment in melanoma: current status and future prospects","volume":"16","author":"Garbe","year":"2011","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2017.12.001_bib2","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/ni.2392","article-title":"Immunology beats cancer: a blueprint for successful translation","volume":"13","author":"Pardoll","year":"2012","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ejca.2017.12.001_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.12.001_bib4","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.12.001_bib5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.12.001_bib6","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.12.001_bib7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.12.001_bib8","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1073\/pnas.94.5.1914","article-title":"A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening","volume":"94","author":"Chen","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2017.12.001_bib9","first-page":"11","article-title":"Expression of the cancer\/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)\u2014correlation with prognostic factors","volume":"7","author":"Velazquez","year":"2007","journal-title":"Canc Immun"},{"key":"10.1016\/j.ejca.2017.12.001_bib10","doi-asserted-by":"crossref","first-page":"8862","DOI":"10.1073\/pnas.1133324100","article-title":"Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses","volume":"100","author":"Gnjatic","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejca.2017.12.001_bib11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ejca.2010.09.042","article-title":"Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate","volume":"47","author":"Svobodov\u00e1","year":"2011","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2017.12.001_bib12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/ijc.28980","article-title":"Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients","volume":"136","author":"Z\u00f6rnig","year":"2015","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejca.2017.12.001_bib13","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1200\/JCO.2011.40.2271","article-title":"Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis","volume":"30","author":"Weide","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.12.001_bib14","doi-asserted-by":"crossref","first-page":"20410","DOI":"10.1073\/pnas.0810114105","article-title":"CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T-cell responses in metastatic melanoma patients with clinical benefit","volume":"105","author":"Yuan","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejca.2017.12.001_bib15","doi-asserted-by":"crossref","first-page":"16723","DOI":"10.1073\/pnas.1110814108","article-title":"Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab","volume":"108","author":"Yuan","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2017.12.001_bib16","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/CJI.0b013e3181affbf0","article-title":"No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma","volume":"32","author":"Goff","year":"2009","journal-title":"J Immunother"},{"key":"10.1016\/j.ejca.2017.12.001_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2017.12.001_bib18","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immunerelated response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2017.12.001_bib19","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1373\/clinchem.2005.052381","article-title":"Multi-plex human papillomavirus serology based on in situ-puri\ufb01ed glutathione S-transferase fusion proteins","volume":"51","author":"Waterboer","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejca.2017.12.001_bib20","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00262-015-1739-8","article-title":"T cell responses in early-stage melanoma patients occur frequently and are not associated with humoral response","volume":"64","author":"Pfirschke","year":"2015","journal-title":"Canc Immunol Immunother"},{"key":"10.1016\/j.ejca.2017.12.001_bib21","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","article-title":"Sample size tables for exact single-stage phase II designs","volume":"20","author":"A'Hern","year":"2001","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2017.12.001_bib22","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.12.001_bib23","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/annonc\/mdu441","article-title":"Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies","volume":"25","author":"Lebb\u00e9","year":"2014","journal-title":"Ann Oncol"},{"issue":"15S","key":"10.1016\/j.ejca.2017.12.001_bib24","article-title":"Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab","volume":"27","author":"Berman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.12.001_bib25","first-page":"449","article-title":"Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma","volume":"63","author":"Kelderman","year":"2014","journal-title":"Canc Immunol Immunother"},{"key":"10.1016\/j.ejca.2017.12.001_bib26","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2217\/imt-2016-0083","article-title":"Use of LDH and autoimmune side effects to predict response to ipilimumab treatment","volume":"8","author":"Dick","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ejca.2017.12.001_bib27","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917314570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917314570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:21:50Z","timestamp":1760732510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917314570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":27,"alternative-id":["S0959804917314570"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.12.001","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}